

























2. A method of detecting and quantitatively evaluat-

ing the severity and spatial extent of ischemic regions in

a human or non-human body, said method comprising the steps of (1) administering into the cardiovascular

system of said hody a contrast enhancing amount of a

the capillary space and surrounding (perfused) tissue resulting in significant signal loss. These results show

that this approach to MR contrast enhancement can be

used to differentiate ischemic from normally perfused 50

A further notable advantage of the method of the

phase encoding steps 32 and 60 of the 128 phase encodingstep acquisitions. FIGS. 23a, b and c and 24a, b and c show 10 the recorded images at 128 and 280 minutes (the (a) images), the contour maps of hypertensity (the (b) images showing the reference areas (100%) of the unaffected hemisphere) and the superpositions of the MR images and the contour maps (the (c) images). At 128 minutes seven different regions of perfusion deficiency were identified. This heterogenicity of the perfusion deficiency is to be expected early in the course of a cerebral ischaemia. At 280 minutes the increased levels of hyperintensity confirm worsening perfusion deficit in most brain regions but the heterogeneity of the hyperintensity suggests that some brain areas may still retain some blood flow.

We claim:

1. A method of monitoring the vasodilatory or vasoconstrictive effects of a physiologically active substance admin- 25 istered to a human or non-human body, said method comprising the steps of: administering said substance into said body; administering into the systemic vasculature of said body a contrast enhancing amount of an intravascular paramagnetic metal containing magnetic resonance imaging 30 contrast agent; subjecting said body to a magnetic resonance imaging procedure capable of generating from magnetic resonance signals from said body a series of temporally speced images of at least a part of said body into which said agent passes, said procedure being a fast imaging procedure 35 having an image acquisition time of less than five seconds; and detecting temporal variations in said signals or images whereby to monitor the vasoconstriction or vasodilation induced by said substance.

2. A method according to claim 1 wherein said contrast 40 agent comprises a physiologically tolerable complex of a paramagnetic lanthanide ion or a physiologically tolerable sait of such a chelate.

3. A method according to claim 2 wherein said contrast agent is a chelate complex of a metal ion selected from the 45 paramagnetic ions of Yb, Tm, Dy, Ho, Er and Gd, or a physiologically tolerable sait thereof.

4. A method according to claim 3 wherein said contrast agent is a chelate complex of Dy(III) or a physiologically tolerable sait thereof. 11. A method according to any one of claims 1, 2, 4 or 8 wherein said procedure is one having an image acquisition time of less than 0.5 seconds.

12. A method according to any one of claims 1, 2, 4 or 8 wherein said procedure is an echo planar imaging procedure.

13. A method according to any one of claims 1, 2, 4 or 8 wherein administration of said contrast agent is by bolus injection.

14. A method according to any one of claims 1, 2, 4 or 8 comprising generating temporally spaced T₂* or T₂-weighted images.

15. A method according to claim 14 wherein said magnetic resonance imaging procedure is a spin-echo or gradient echo procedure.

16. A method according to claim 14 comprising generating and comparing T₁-weighted images or signals transformable thereto and T₂* or T₂-weighted images or signals transformable thereto whereby to identify body regions in which blood perfusion occurs.

17. A method according to claim 1 being a method of detecting body regions of blood flow deficit in which blood perfusion is thermally or chemically modified.

18. A method according to claim 1 wherein said contrast agent comprises a physiologically tolerable complex of a paramagnetic transition metal ion or a physiologically tolerable salt of such a chelate.

19. A method according to claim 8 wherein said contrast agent is administered as a contrast medium composition comprising DyDTPA-BMA and CaNaDTPA-BMA in a molar ratio of about 20:1.

20. A method of monitoring the vasodilatory or vasoconstrictive effects of a physiologically active substance administered to a human or non-human animal body said method comprising administering said substance into said body, administering into the systemic vasculature of said body a contrast enhancing amount of an intravascular paramagnetic metal containing magnetic susceptibility magnetic resonance imaging contrast agent, subjecting said body to a magnetic resonance imaging procedure capable of generating from magnetic resonance signals from said hody a series.

some blood flow. We claim:

1. A method of monitoring surgically induced blood perfusion variations, said method comprising administering a contrast enhancing amount of an intravascular paramagnetic metal containing magnetic susceptibility magnetic resonance imaging contrast agent into the systemic vascu
14. A method according to claim 1 wherein said magnetic resonance imaging procedure is an echo planar imaging lature of a human or animal body which is undergoing or has undergone surgery, subjecting said body to a magnetic resonance imaging procedure capable of generating from magnetic resonance signals from said body a series of temporally spaced images of at least a part of said body into 30 which said agent passes, and detecting temporal variations, in said signals or images whereby to identify regions of surgically induced variations in blood perfusion.

in the course of a cerebral ischaemia. At 280 minutes the

increased levels of hyperintensity confirm worsening perfu-

sion deficit in most brain regions but the heterogeneity of the hyperintensity suggests that some brain areas may still retain

2. A method according to claim 1 wherein said contrast agent comprises a physiologically tolerable complex of a 35 paramagnetic lanthanide ion or a physiologically tolerable

salt of such a chelate.

3. A method according to claim 2 wherein said contrast agent is a chelate complex of a metal ion selected from the paramagnetic ions of Yb, Tm, Dy, Ho, Er and Gd, or a 40 physiologically tolerable salt thereof.

4. A method according to claim 3 wherein said contrast agent is a chelate complex of Dy(III) or a physiologically

tolerable salt thereof.

5. A method according to claim 1 wherein said contrast 45 agent comprises a physiologically tolerable non-ionic paramagnetic lanthanide chelate complex.

6. A method according to claim 2 wherein said chelate complex is a complex of a linear, branched or macrocyclic chelant selected from polyaminopolycarboxylic acid

agent is administered at a dosage of 0.08 to 0.5 mmol/kg bodyweight.

11. A method according to claim 1 wherein said magnetic resonance imaging procedure is a fast imaging procedure.

12. A method according to claim 11 wherein said fast imaging procedure is one having an image acquisition time 20 of less than 5 seconds.

13. A method according to claim 11 wherein said fast imaging procedure is one having an image acquisition time of less than 0.5 seconds.

procedure.

15. A method according to claim 1 comprising generating temporally spaced T₂* or T₂-weighted images.

16. A method according to claim 15 wherein said magnetic resonance imaging procedure is a spin-echo or gradient echo procedure.

17. A method according to claim 15 comprising generating and comparing T1-weighted images or signals transformable thereto and T_2^{\bullet} or T_2 -weighted images or signals transformable thereto whereby to identify body regions in which blood perfusion occurs.

18. A method according to claim 1 being a method of detecting body regions of blood flow deficit.

19. A method according to claim 18 being a method of detecting ischemic regions.

20. A method according to claim 1 wherein said contrast agent comprises a physiologically tolerable complex of a paramagnetic transition metal ion or a physiologically tolcrable salt of such a chelate.

21. A method according to claim 1 wherein said contrast agent is administered as a contrast medium composition comprising DyDTPA-BMA and CaNaDTPA-BMA in a molar ratio of about 20:1.